Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dy...

Related Keywords

Jordan ,China ,Markj Foley ,Fosun Pharma ,Guidepoint Qsight ,Laurence Watts ,Jessica Serra ,Securities Exchange ,Foley ,Gilmartin Group ,Allergan Inc ,China National Medical Products Administration ,Viatris Inc ,Revance Therapeutics Inc ,Exchange Commission ,Linkedin ,Revance Therapeutics ,Athyrium Capital ,Note Purchase Agreement ,Chief Executive Officer Mark ,Quarter Highlights ,Erica Jordan ,Senior Vice President ,Chief Commercial Officer ,National Medical Products Administration ,Shanghai Fosun Pharmaceutical ,Resilient Hyaluronic Acid ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Consolidated Statements ,Months Ended September ,